SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart Failure.
No Thumbnail Available
All Authors
Campbell, RT.
Osmanska, J.
Docherty, KF.
Ahmed, FZ.
Clark, AL.
Clayton, L.
Cleland, JGF.
Critoph, C.
Dewhurst, M.
Hartshorne-Evans, N.
LTHT Author
Gatenby, Kate
LTHT Department
Cardio-Respiratory
Cardiology
Cardiology
Non Medic
Publication Date
2026
Item Type
Journal Article
Language
Subject
AMBULATORY CARE , DIURETICS , HEART FAILURE , RANDOMISED CONTROLLED TRIALS
Subject Headings
Abstract
INTRODUCTION: Heart failure (HF) hospitalizations are frequent and lengthy, and usually involve treatment with intravenous diuretics to relieve congestion. SUBCUT HF II is evaluating the safety and efficacy of an alternative ambulatory care strategy using a novel subcutaneous formulation of furosemide delivered via a wearable pump.
METHODS: The SUBCUT HF II trial is a multicentre, randomized, active comparator trial involving 20 hospitals in the UK. Eligible participants are patients with HF receiving inpatient treatment with intravenous loop diuretic. Patients are randomized to either early supported discharge, using a novel formulation of subcutaneous furosemide (SQIN-Furosemide) administered by a wearable pump (SQIN-Infusor), or continued inpatient treatment using intravenous furosemide.
RESULTS: The primary endpoint is days spent alive and out of hospital at 30 days. As of October 2025, 168 of 170 patients have been randomized.
CONCLUSION: The SUBCUT HF II trial is testing the safety and efficacy of an ambulatory care approach to managing patients presenting to the hospital with HF.
TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT05419115.
Journal
European Journal of Heart Failure